Jie Hao

Jie Hao


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 February 2025 in Apoptosis
Verified
Journal Article
Closed access
PDF file
WPWen Pan
Wen Pan
YHYueting Han
Yueting Han
MZMingqing Zhang
Mingqing Zhang
KZKegan Zhu
Kegan Zhu
ZYZhen Yang
Zhen Yang
HZHaiyang Zhang
Haiyang Zhang

1 July 2024 in Clinical Interventions in Aging
Verified
Journal Article
Open access
PDF file
YGYing Gao
Ying Gao
JHJie Hao
Jie Hao
ZZZhendong Zhang
Zhendong Zhang
Decision-making regarding adjuvant chemotherapy for older adults with breast cancer is a challenge because older adult patients often have poor physical health, frailty, and age-related comorbidities, which can compromise treatment outcome. Due to these considerations, doctors tend to use less chemotherapy for breast cancer in older adults. However, older patients in good general health could still benefit from chemotherapy. Careful benefit-risk assessment is essential to provide best care for each older adult patient. Due to a rapidly aging population, breast cancer in older adults is becoming a serious public health issue in China. In this mini review, we discuss the need, means, and tools to assess the benefits and risks of adjuvant chemotherapy in older adults with breast cancer. The contents of this review may drive decision-making with regard to the use and selection of adjuvant chemotherapy for older adult patients in China who are fit for the treatment.

25 October 2024 in Bioconjugate Chemistry
Verified
Journal Article
Closed access
SWShoujun Wang
Shoujun Wang
XBXinwei Bai
Xinwei Bai
XWXiaoya Wang
Xiaoya Wang
JWJinmiao Wang
Jinmiao Wang
WTWeijie Tao
Weijie Tao
MGMing Gao
Ming Gao

15 September 2024 in International Journal of Biological Macromolecules
Verified
Journal Article
Closed access
QSQi Sun
Qi Sun
ZYZhen Yang
Zhen Yang
MQMinghan Qiu
Minghan Qiu
SWShoujun Wang
Shoujun Wang
XZXingli Zhao
Xingli Zhao
MGMing Gao
Ming Gao

6 April 2025 in Discover Oncology
Verified
Journal Article
Open access
PDF file
YGYing Gao
Ying Gao
JWJinmiao Wang
Jinmiao Wang
WTWeijie Tao
Weijie Tao
SWShoujun Wang
Shoujun Wang
HXHai Xie
Hai Xie
MGMing Gao
Ming Gao
Background Primary thyroid lymphoma (PTL) is a rare and aggressive malignancy with a need for more precise prognostication tools due to the limitations of existing staging systems. This study aims to develop a nomogram to predict overall survival (OS) rates in PTL patients, addressing the gap in personalized treatment protocols. Methods We analyzed 1469 PTL cases. Cox regression analyses were used to identify key prognostic factors and construct a survival prognostic nomogram. The nomogram’s performance was evaluated using receiver operating characteristic (ROC) curves and decision curve analysis. Additionally, a web-based dynamic nomogram was developed to estimate mortality risk for PTL patients. Results The nomogram exhibited high clinical utility and precision as determined by decision curve analysis and ROC curves. Furthermore, a novel risk stratification system was introduced. Kaplan–Meier survival curves illustrated significant differences among various risk groups, reinforcing the nomogram’s substantial clinical value in predicting OS for PTL patients (P < 0.0001). SHAP value analysis clarified each variable’s specific impact on the outcome. Conclusions The nomogram provides a valuable instrument for clinicians to individualize OS predictions for PTL patients, addressing the unmet need for personalized prognostication in this rare malignancy.

1 July 2025 in Gland Surgery
Verified
Journal Article
Open access
PDF file
YGYing Gao
Ying Gao
LLLei Liu
Lei Liu
SWShoujun Wang
Shoujun Wang
WTWeijie Tao
Weijie Tao
JWJinmiao Wang
Jinmiao Wang
MGMing Gao
Ming Gao
Background: Breast cancer (BC) is the leading cancer in women. It often metastasizes to bone, worsening the prognosis. Diagnostic methods often fail to predict bone metastasis (BM). This study developed a machine learning (ML) model using the Surveillance, Epidemiology, and End Results (SEER) database for BM prediction, to refine treatments and improve outcomes. Methods: Using SEER data, we studied 24,584 BC patients diagnosed 2010–2015 with radiologically confirmed BM. Tumor size, grade, tumor (T)/node (N) stages, and estrogen receptor (ER)/progesterone receptor (PR)/human epidermal growth factor receptor 2 (HER2) status were assessed. Stratified randomization divided the data into 70% training (n=18,438) and 30% validation (n=6,146). Six ML algorithms were developed, emphasizing random forest (RF). Receiver operating characteristic (ROC) curve analysis [area under the curve (AUC), sensitivity, specificity, negative predictive value (NPV)] assessed performance. The SHapley Additive exPlanations (SHAP) framework identified key BM predictors. Results: Our analysis of 24,584 patients identified 1,298 (5.26%) patients with BM. Logistic regression (LR) provided the highest specificity [0.897, 95% confidence interval (CI): 0.889–0.905], contrasting with gradient boosting machine (GBM)’s maximal sensitivity (0.658, 95% CI: 0.609–0.707). With sensitivity at 0.658, better algorithms or multimodal methods are needed for case identification. The multilayer perceptron neural network (MLPNN) model demonstrated superior performance, with the highest AUC of 0.808 (95% CI: 0.798–0.818), surpassing the LR and adaptive boosting (AdaBoost) models, both with AUCs of 0.803 (95% CI: 0.793–0.813). The RF model was particularly adept at ruling out BM, with an NPV above 97%. The SHAP analysis identified tumor size, grade, T/N stages, ER/PR/HER2 status, and brain/liver/lung metastases as key predictors for risk stratification. Decision curve analysis showed RF’s superior utility over the American Joint Committee on Cancer (AJCC) Staging System. Conclusions: Our ML model demonstrates potential for predicting BM in patients with BC. It may serve as a clinical aid to identify at-risk individuals early. However, moderate sensitivity requires refinement for better case detection. This study supports integrating ML into clinical practice, advancing personalized oncology medicine.